In addition to colorectal carcinoma, gastric cancer (GC), and biliary tract cancer, the combination of regorafenib and anti-PD-1/PD-L1 therapies has also shown promising therapeutic effects in HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.